Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The product of SSX1 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. Additionally we are shipping Synovial Sarcoma, X Breakpoint 1 Antibodies (30) and many more products for this protein.
Showing 5 out of 6 products:
Human SSX1 Protein expressed in Escherichia coli (E. coli) - ABIN1098779
Nilsson, Skytting, Xie, Brodin, Perfekt, Mandahl, Lundeberg, Uhlén, Larsson: The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. in Cancer research 1999
Show all 2 references for ABIN1098779
Human SSX1 Protein expressed in Wheat germ - ABIN1321448
Smith, Cronk, Lang, McNeel: Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. in Cancer research 2011
a rare variant of the SS18 (show SS18 Proteins)-SSX1 fusion transcript, which could not be identified by routine procedures for genetic diagnosis, was detected. In addition, 8 missense mutations of cancer-related genes were confirmed
SS18 (show SS18 Proteins)-SSX (show SSX2 Proteins)-induced Wnt (show WNT2 Proteins)/beta-catenin (show CTNNB1 Proteins) signaling appears to be of crucial biological importance in synovial sarcoma tumorigenesis and progression.
The mRNA levels of SSX1 and SSX4 are associated with multiple myeloma clinical stage
These results suggest that the characteristic speckle localization pattern of SS18 (show SS18 Proteins)-SSX (show SSX2 Proteins) is strongly involved in the tumorigenesis through the SSX (show SSX2 Proteins) moiety of the SS18 (show SS18 Proteins)-SSX (show SSX2 Proteins) fusion protein.
Knockdown of SS18 (show SS18 Proteins)-SSX1 in synovial sarcoma inhibits viability and induces apoptosis.
Study shows that the SS18 (show SS18 Proteins)-SSX1 oncogenic fusion usurps SWI (show SMARCA1 Proteins)/SNF (show SNRPA Proteins)-like BAF (show BANF1 Proteins) complexes, resulting in activation of Sox2 (show SOX2 Proteins), which drives proliferation.
siRNA targeting of SS18 (show SS18 Proteins)-SSX1 has therapeutic potential for the treatment of synovial sarcoma.
epigenetic features may define the cellular microenvironment in which SYT (show SS18 Proteins)-SSX (show SSX2 Proteins) displays its functional effects
existence of fusion with SYT (show SS18 Proteins) in synovial sarcoma
A synovial sarcoma of classic morphology contained a novel t(20;X) SS18L1 (show SS18L1 Proteins)(strong homology to SS18 (show SS18 Proteins) on Ch20)/SSX1 fusion transcript in which nucleotide 1216 (exon 10) of SS18L1 (show SS18L1 Proteins) was fused in-frame with nucleotide 422 (exon 6) of SSX1.
The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X\\\\;18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity.
, cancer/testis antigen 5.1
, cancer/testis antigen family 5, member 1
, sarcoma, synovial, X-chromosome-related 1
, synovial sarcoma, X breakpoint 1